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In 2002 a consensus statement pertaining to the management of classical congenital adrenal hyperplasia due to 21-hydroxylase
deﬁciency was jointly produced by the Lawson Wilkins Pediatric Endocrine Society and the European Society of Pediatric
Endocrinology. One of the recommendations of this consensus was that centers should maintain multidisciplinary teams for
providing care and support to these patients and their families. However, the speciﬁcs for how this should be accomplished were
notaddressedintheoriginalconsensusstatement.Hereweinterpretandtranslatethe2002consensusstatementrecommendations
into medical, surgical and mental health protocols. Additionally, we provide preliminary evidence that such protocols result in
improved care and support for patients and families.
1.Introduction
Congenital adrenal hyperplasia (CAH) is an autosomal
recessive disorder due most commonly to a deﬁciency of 21-
hydroxylase (21-OH) enzyme action that typically reduces
cortisol and aldosterone secretion while simultaneously
increasing androgen production [1]. Cortisone therapy to
treat CAH was introduced in the early 1950s. Since that
time, mortality from CAH has decreased as physicians and
other healthcare professionals have gained knowledge and
experience with the medical treatment of this disorder [2, 3].
Despite these gains, optimal treatment of CAH remains
elusive[4].Aconsensusstatementin2002bymembersofthe
Lawson Wilkins Pediatric Endocrine Society (LWPES) and
the European Pediatric Endocrine Society (ESPE) attempted
to “...consider the best practice, to formulate management
guidelines, and to consider innovative therapies ...” related
to 21-OH deﬁciency [4].
An important recommendation of the consensus was
to organize and maintain a multidisciplinary team for
providing medical, surgical, educational, mental health, and
family support services to patients and their families [4].
Unfortunately, speciﬁc protocols for managing hormone
levels during medical therapy, providing education about
the pros and cons of feminizing genitoplasty, and how/when
to introduce patients to mental health services and support
groups were not oﬀered [5]. The goals of this paper are to
describe our multidisciplinary team approach to providing
evidence-based care to patients and families aﬀected by 21-
OH deﬁciency, and to assess the eﬀectiveness of having such
a clinic. Included is an interpretation and translation of
the 2002 consensus statement recommendations into clinical
practice, education, and social support protocols.
2. BuildingTeam Structureand
Communication between Members
The 2002 consensus statement recommends that “A well-
organized multidisciplinary team (including specialists in2 International Journal of Pediatric Endocrinology
pediatric endocrinology, psychosocial services, pediatric
surgery/urology, and genetics) is essential...”a n d“ i ti s
importantthatthecoordinatoroftheteamhasanexperience
in the long-term care of the patient with CAH and provides
a consistent message to patients [4].” The CAH team
at the Children’s Hospital of Oklahoma is comprised of
professionals in the areas of nursing, newborn screening,
pediatricendocrinology,adultendocrinology,pediatricurol-
ogy, child psychiatry, and behavioral endocrinology. Genetic
consultation is available on a case-by-case basis, but is
not routinely obtained for all of our patients. Members
of our team have conducted long-term studies of physical
and mental health outcomes of patients aﬀected by 21-
OH deﬁciency as recommended by the 2002 consensus [4].
Resultsfromthesestudies,inadditiontoothers,wereusedto
plan the clinic protocols and are included in the educational
material provided to patients and their families. This has
led to the inclusion of an adult endocrinologist to allow
for transition services and support to individuals aﬀected by
CAH throughout the lifespan.
Ourteamiscoordinatedbyanurseemployedbythestate
newborn screening program of Oklahoma. This nurse acts as
the clinic coordinator and is the ﬁrst point of contact to all
families when a child is diagnosed with 21-OH deﬁciency via
the state newborn screening program. The clinic coordinator
also initiates communication with aﬀected families not
identiﬁed by the state newborn screening program in the
context of support groups. The clinic coordinator’s contact
information is provided on our website and on business
cards that are distributed to patients and their families. The
decision to have the newborn screening nurse act as the
clinic coordinator was made to reduce confusion for families
about whom to call when they need to reach a team member.
All patients and parents are instructed to contact the clinic
coordinator and she then contacts the appropriate team
member for each case.
In addition to serving as the point-of-contact, the clinic
coordinator also schedules joint clinic visits with pediatric
urology, psychiatry, and pediatric endocrinology or adult
endocrinology, depending upon patient needs. Furthermore,
the clinic coordinator organizes apatient chart reviewforthe
team of providers at least 24 hours prior to clinic visits and
also monthly journal club meetings to ensure that our team
is developing and following evidence-based management
protocols.
3. ProvidingTeam Communication to
Patientsand Families
The CAH team meets with families of aﬀected newborns at
the bedside if they are at our home institution. If not, the
family is invited to the Children’s Hospital of Oklahoma for
a family conference. This conference is open to family mem-
bers and friends that parents wish to include. During these
meetings education about 21-OH deﬁciency is provided
which includes handouts, national support group contact
information, and our regional support group schedule.
The 2002 consensus statement indicates that “Monitor-
ing may be accomplished based on physical and hormonal
ﬁndings suggestive of excessive or inadequate steroid therapy
[4].” Our team’s protocol for a newborn identiﬁed through
state screening begins as soon as newborn screening results
are available, typically by 1 week of life. Initial education is
provided at that time (please refer to Developing CAH Edu-
cation for Patients, Families, and School Personnel). A medical
treatment plan and schedule of monitoring, including the
type and frequency of laboratory tests, bone age (BA) x-rays,
andclinicvisitsbydevelopmental stageisprovidedtoallnew
patients and is also available on our website (see Table 1).
If children older than 3 years of age exhibit good
hormonal control (indicated by a BA within normal limits
after the age of 2 years, a growth velocity within normal
limits, an androstenedione level within normal limits, and
a 17-hydroxyprogesterone (17-OHP) level between 400–
1200ng/dL) [1], then they will be scheduled for clinic visits
every4monthsuntilepiphysealfusion.Forthosewhodonot
exhibit good control, more frequent visits are scheduled.
Communication with families of established patients
includes a letter with upcoming appointment dates/times
accompanied by a laboratory order sent 4 weeks prior to the
next visit. Patients or parents are then called by the newborn
screening nurse 48 hours prior to their appointment to
ensure that appropriate laboratory studies were obtained.
Patients who miss an appointment (our no-show rate is
<5%) are called by the clinic coordinator within 1 week to
reschedule and reiterate the importance of medical visits.
4.Mental HealthServicesandSupportGroups
The 2002 consensus statement indicates “Psychological
assessment and support of the patient and his/her family
should be a routine component of the comprehensive care
and management of these patients. Parents and/or patients
should be oﬀered the option of age- and sex-appropriate
psychological counseling at the time of the initial diagnosis
[4].” The majority (95%) of girls and women with CAH
develop a female gender identity regardless of their degree of
genital masculinization at birth [6]. However, these women
reportpoorerqualityoflifeinaddition togreaterdepression,
anxiety, and suicidal thoughts than unaﬀected women [7].
Therefore, mental health services and peer support are
needed even though gender dysphoria is rare. All patients
and families in our clinic are introduced to the child
psychiatrist member of our team and oﬀered information
about online and in-person support groups within the ﬁrst
3 months of diagnosis. Patients and families meet with
the child psychiatrist at least annually, and more frequent
appointmentsareavailableasrequestedtodiscussissuessuch
as depression and anxiety.
Although gender identity consistently develops in a
female-directed manner, gender role behaviors such as play
and aggression are often masculinized in girls and women
with CAH. Girls with CAH sometimes prefer toys and games
[8], and exhibit levels of aggression [9], typically associated
with boys. Additionally, women with null mutations of theInternational Journal of Pediatric Endocrinology 3
Table 1: Typical multidisciplinary protocol for the CAH clinic at The Children’s Hospital of Oklahoma.
AGE Objectives Visit
Schedule Labs Education Urology Psychiatry Support
Group
1st Month
(i) Metabolic stability
(ii) Provide parents with
an understanding of
disease and treatment
1, 2 & 4wks
(i) CAH panel every
visit
(ii) Electrolytes every
visit
(i) Meets with RN
each visit re: medical
regimen and stress
dosing
Up to
3 years
(i) Establish optimal
medical regimen
(ii) Feminizing surgery
as needed for females
Every 3mos
(i) CAH panel every
visit
(ii) Electrolytes
through 1st year
(iii) BA yearly starting
at age 2
(i) Meets with RN
each visit re: medical
regimen
(ii) Meets with RN
annually re: stress
dosing, medic alert,
and CAH quiz
Females see
urologist at 3,
6, 12 months
3, 12, and
24mo
Every
4mos
3yto
adolescence
(i) Adjust medical
regimen to maintain
normal growth and
health
(ii) Increase child’s
understanding of
condition as appropriate
for age
Every 4mos
(i) CAH panel every
visit
(ii) BA yearly until
epiphyseal fusion
(i) Meets with RN
each visit re: medical
regimen
(ii) Meets with RN
annually re: stress
dosing, medic alert,
and CAH quiz
Females see
urologist
prior to
menarche
Annually
or more
often as
needed
Every
4mos
Adolescence
(i) Adjust medical
regimen to maintain
normal growth, pubertal
development and
maintain health
(ii) Increase child’s
understanding of
condition as appropriate
for age
(iii) Follow-up with
Urology for females
Every 4mos
(i) CAH panel every
visit
(ii) Annual testicular
exam for boys
(i) Meets with RN
each visit re: medical
regimen
(ii) Meets with RN
annually re: stress
dosing, medic alert,
and CAH quiz
Females see
urologist
prior to
becoming
sexually
active
Annually
or more
often as
needed
Every
4mos
Adulthood (i) Transition to adult
medical care Annually CAH panel every visit As needed
Annually
or more
often as
needed
Every
4mos
CYP21A2 gene (a marker of greater exposure to prenatal
androgens) are more likely to choose masculine occupations
and to exhibit interest in contact sports and motor vehicles
despite having a female gender identity [10]. However,
when retrospectively queried about their relative degrees
of feminine/masculine behavior, most women with CAH
reportincreasedfeminizationanddecreasedmasculinization
with age [11]. While the majority of women aﬀected by
CAH report a heterosexual orientation, homosexuality, and
bisexuality are more frequently reported than in unaﬀected
females [12, 13] .S i m i l a rt og e n d e rr o l e ,w o m e nw i t hn u l l
mutations of the CYP21A2 gene are most likely to report
sexualattractiontootherfemales[10].Theseareexamplesof
nonpathologicbehavioraldevelopmentassociatedwithCAH
that some people prefer to discuss in peer support group
environments rather than, or in addition to, clinical settings.
Cognition is a ﬁnal aspect of behavioral health that is
purported to be inﬂuenced by CAH. While some reports
conclude that girls and women with CAH exhibit spatial
processing abilities similar to males, most fail to ﬁnd
consistent diﬀerences between girls and women with CAH
and unaﬀected females [8, 14]. Finally, limited behavioral
data from children at risk for CAH who were treated
with dexamethasone prenatally indicate that verbal working
memory [15], but not temperament [16], is aﬀected by this
therapy. As more children are exposed to dexamethasone
prenatally, further long-term behavioral studies will be
needed to guide clinical management of these children.
Because the evidence does not support major cognitive
diﬀerences due to CAH, our clinical protocol does not
routinely include neuropsychological assessment.
In contrast to the increased masculinization of overt
gender role and sexual orientation with disease severity,
patients’ perceptions of the impact of their disease on
their relationships with others are not associated with the
degree of their 21-OH deﬁciency. Rather, mental health
and educational support of patients and their families are
better predictors of psychological adaptation [10]. In an
eﬀort to provide ongoing support and education to patients
and families, local support groups for CAH are oﬀered4 International Journal of Pediatric Endocrinology
by the Children’s Hospital of Oklahoma 3 times per year.
These meetings are discussion-oriented and include fun
activities designed to facilitate socialization among group
members. The adult endocrinologist in our group attends
thesemeetingssothatyoungerpatientsandtheirfamiliescan
interact with her prior to transitioning their care. Online and
face-to-face peer support and education are also available via
the CARES (http://www.caresfoundation.org/)a n dM A G I C
(http:/www.magicfoundation.org/) Foundations.
5. Developing CAH Education for Patients,
Families,and School Personnel
Initial education about 21-OH deﬁciency is provided by
the clinic coordinator and includes a discussion of the
hypothalamic-pituitary-adrenal (HPA) axis, negative feed-
back to maintain normal hormone production, and the
underlying pathophysiology and genetics of CAH. A folder
containing general information about CAH, Cortef, ﬂu-
drocortisone, and national support groups is provided.
Also provided in this folder is contact information for
our clinic and emergency management. Oral and injectable
stress dosing of glucocorticoids is emphasized in the initial
education session, and a summary of this information is also
provided in the folder. At the ﬁrst education session, patients
and parents are provided with a laminated emergency
room (ER) card that includes contact information for the
team’s pediatric endocrinologists and contact information
regarding days, nights and weekends, and instructions for
intravenous(IV)ﬂuidandglucocorticoidadministration.All
f a m i l i e sa r eg i v e nac o p yo fH s ua n dR i v k e e s ’Congenital
Adrenal Hyperplasia: A Parent’s Guide [17]t ot a k eh o m e
as well. Parents are also provided with a “CAH emergency
kit” containing a thermometer and everything needed to
giveanemergencyintramuscular(IM)injectionofhydrocor-
tisone hemisuccinate (Solu-Cortef). Medical identiﬁcation,
for example, a Medic-Alert bracelet, is ordered by the clinic
coordinator for all patients within the ﬁrst 2-3 months of
joining our clinic.
Continuing education about CAH is provided to patients
and families by the clinic coordinator at each visit. Patho-
physiology is reviewed and patient/parent questions are
addressed if patients or parents have contacted our team
for emergency management, that is discussed. A review of
stress dosing (oral and injection) occurs at each visit, the
importance of wearing medical identiﬁcation is emphasized,
and replacement emergency kits are provided as needed.
A quiz is administered to adult patients and parents of
aﬀected children to ensure that information about CAH
has been successfully conveyed [18]. Those who do not
show a complete understanding of this information are
provided with additional education. Annually, older patients
and parents are asked to demonstrate competency giving a
Solu-Cortef injection. At that time families are also provided
replacement ER cards as needed.
Educational material is provided to school personnel
by the clinic coordinator when requested. This includes a
medical letter describing the signs of adrenal insuﬃciency,
how and when to administer a stress dose of glucocorticoid
orally and intramuscularly, and how to contact the CAH
team in emergency situations. Upon request the clinic
coordinator travels to schools attended by patients to give
a presentation on emergency management for CAH. This
presentation lasts approximately 45 minutes and allows
school staﬀ to practice administering Solu-Cortef injections.
Children receive age-appropriate education about the
endocrine system, CAH speciﬁcally, puberty, and why they
visit our clinic. When a patient enters puberty, they receive
information about the genetics of CAH and contraception.
Boysreceiveinformationabouttesticularadrenalresttumors
a n da r ei n s t r u c t e do nh o wt op e r f o r mt e s t i c u l a rs e l f - e x a m s .
Girls receive information about sexual function following
genitoplasty (if such procedures have been performed), and
are examined by a pediatric urologist at adolescence to
determine the potential for peno-vaginal intercourse.
6. ClinicalEvaluation
6.1. Growth. Linear growth rate throughout childhood, as
well as ﬁnal adult height, are important measures for
assessing the adequacy of medical treatment [19]. Under-
treatment with glucocorticoid results in hyperandrogenism
and premature fusion of the epiphyses [20], while over-
treatment impairs growth velocity [21]. The result of either
sustained under- or over-treatment results in a ﬁnal height
that is less than that expected from an individual’s genetic
potential. Factors that have been identiﬁed that modulate
growth velocity and ﬁnal height include the age at diagnosis
a n dt h et y p ea n dd o s eo fg l u c o c o r t i c o i dr e p l a c e m e n tu s e d
[19, 22–27]. Thus, careful height measurement is recom-
mended for each clinic visit, including an interval height
velocity calculation, to optimize medical management.
6.2. Weight. Monitoring weight is also recommended for
patients with CAH [4]. When height, weight, and BMI
were retrospectively analyzed at 1, 5, and 10 years of age,
BMI signiﬁcantly increased at years 5 and 10 in children
with CAH [28]. An increased BMI puts children at risk for
future complications such as polycystic ovarian syndrome
(females), type 2 diabetes, and cardiovascular disease. Thus,
we record weight and calculate BMI at each visit. Those
patientswithincreasedBMIarecounseledonimprovingdiet
and physical activity.
6.3. Blood Pressure Monitoring. Prolonged exposure to min-
eralocorticoids is associated with elevated blood pressure
and as a result routine monitoring of blood pressure is
recommended in patients with CAH [4]. When ambulatory
pressure is monitored, mean systolic values are signiﬁcantly
higher in children and adolescents compared to unaﬀected
controls [29]. Blood pressure is monitored at every clinic
visit as hypertension places people at risk for cardiovascular
disease.
6.4. Laboratory Measures. Select laboratory parameters are
used to guide adequacy of hormonal replacement. These areInternational Journal of Pediatric Endocrinology 5
obtained every 3 months for the ﬁrst 2 years of life and
every 4 months thereafter. Circulating concentrations of 17-
OHP, androstenedione, and testosterone (except for sexually
maturemales)aremeasuredtojudgethesuﬃciencyofgluco-
corticoid replacement. Plasma renin activity and electrolytes
are used to assess the replacement dose of mineralocorticoid
[4]. Serum electrolytes are measured routinely during the
ﬁrst year of life only, as aberrant measures are not expected
in individuals receiving proper medical treatment later in
life.
Blood samples are obtained in the morning before the
ﬁrst medication dose to improve consistency of the 17-
OHP measurement as this varies greatly with respect to
time of day and glucocorticoid dose [30]. We aim for
levels of androstenedione, testosterone, and plasma renin
activity to be in the normal range for prepubertal chil-
dren, whereas modest elevations of 17-OHP are accepted.
During adolescence, androstenedione and testosterone levels
should rise in concert with the appearance of a normal
puberty.
It is important to recognize that laboratory measures
are more sensitive in the detection of under- compared to
over-treatment. 17-OHP concentrations that are persistently
suppressed below the target range of 400–1200ng/dL prob-
ably indicate excessive glucocorticoid replacement [1], but
need to be interpreted in light of other clinical parameters
such as growth rate and BA progression. Testosterone
levels that exceed those expected in prepubertal children
certainly indicate inadequate glucocorticoid replacement
[1]. Elevated renin indicates insuﬃcient intake of either
mineralocorticoid replacement or salt. It is essential to
correct mineralocorticoid insuﬃciency as this may make
the standard glucocorticoid dose less eﬀective in controlling
adrenocortical activity [31].
6.5. Bone Age. The utility of monitoring BA for assessing
growth and predicting growth potential is undisputed [32].
BA is monitored annually in our patients, starting at the age
of 2 years and stopping when epiphyseal fusion is complete.
When clinically indicated, such as at the onset of puberty
or a change in growth velocity is detected, BA may be
measured as frequently as every 6 months. BA reports are
read by an experienced radiologist as well as the pediatric
endocrinologist who cares for each patient. Our aim is
to achieve normal BA advancement, and thus growth, by
optimizing glucocorticoid replacement for each patient.
6.6. Testicular Adrenal Rest Tumors. The prevalence of
testicular adrenal rest tumors (TART) in males aﬀected
by 21-OH deﬁciency varies greatly (0–95%) across studies
[33–35]. This variance is due to diﬀerences in patient
age, disease severity, and medical management, as well
as diﬀerent methodologies employed for tumor detection.
Though TART may be found prior to puberty by ultrasound,
the clinical signiﬁcance of this is uncertain. Therefore, our
protocol for evaluation of TART includes annual testicu-
lar examination beginning at puberty. Abnormal ﬁndings
revealed by testicular examination are subsequently evalu-
ated by a scrotal ultrasound [36].
7. EndocrineManagement
7.1. Glucocorticoid Dosing. The optimal glucocorticoid dose
replaces deﬁcient endogenous cortisol, prevents virilization,
optimizesgrowth,andprotectsfertility[4].Thenormaldaily
production rate of cortisol is approximately 6mg/m2/day;
however, doses of 12 to 15mg/m2/day or higher are typi-
cally needed to adequately reduce androgen overproduction
[37]. Recommended glucocorticoid replacement is with 10–
15mg/m2/day of hydrocortisone divided into 3 daily doses,
with doses as high as 25mg/m2 during infancy [38]. Treat-
ment with hydrocortisone, prednisone, or dexamethasone
can result in normal growth if therapy is initiated before the
BA advances beyond chronological age [22, 39]. At the com-
pletion of linear growth, the consensus statement gives the
option of changing to prednisolone 2–4mg/m2 twice daily
or dexamethasone 0.25–0.375mg/m2 once daily [4]. Our
clinic’sprotocolforglucocorticoiddosingstatesthatchildren
are started on Cortef tablets 10–20mg/m2, administered in
3 doses approximately 8 hours apart with the largest dose
given in the morning [40]. Dexamethasone is considered for
patients who have ﬁnished growing or for whom compliance
issues necessitate once-daily dosing. Overall, doses are
adjusted based on values of 17-OHP, androstenedione, and
testosterone along with BA and growth data.
7.2. Mineralocorticoid Dosing and Salt Supplementation. All
patients are initially prescribed a daily dose of 0.1mg of
ﬂudrocortisone. This dose is then titrated based on plasma
renin activity levels and blood pressure measurements [4].
Forinfants,electrolytesarealsoconsideredwhentitratingthe
mineralocorticoid replacement. All patients not exclusively
fed table food are supplemented with sodium chloride, 2-
3g/day, distributed in breast milk or formula throughout
the day. Parents are given a test tube marked with the
amount ofsaltthat needs to be supplementeddaily. Diﬀerent
methods of salt supplementation techniques have been
eﬀective for our patients (e.g., medication paciﬁers, adding
small amounts of salt/salt water to each feeding).
7.3. Glucocorticoid Dosing and Emergency Management. For
stress dosing, the 2002 consensus statement recommends
that “...patients should be given increased doses of gluco-
corticoids during febrile illness (>101F), when vomiting or
when unable to take oral feedings, after trauma, and before
surgery” and “Stress dosing should be 2-3 times the main-
tenance glucocorticoid dose for patients able to take oral
medications [4].” Patients in our clinic are instructed to take
a triple dose of oral medication in the case of minor illness or
injury,suchasafeverexceeding101
◦F,vomitingonce,sprain,
or ear infection. They are also instructed to take a triple dose
of medication for 2-3 days following a major stressor such
as a broken bone or pneumonia. Parents can give oral stress
doses without notifying our team until after the fact. The
2002 consensus statement recommends that “Guidelines for
IV bolus and subsequent doses are as follows: for children
younger than 3yr of age, 25mg followed by 25–30mg/d;
for children 3–12yr of age, 50mg followed by 50–60mg/d;
and for adolescents and adults, 100mg followed by6 International Journal of Pediatric Endocrinology
100mg/d[4].”TheuseofhomeIMSolu-Cortefisadvisedfor
major illness or injury, such as severe trauma or dehydration.
Parents are instructed to administer IM Solu-Cortef anytime
their child cannot take pills by mouth, followed promptly by
a visit to the ER if the situation is severe or persistent.
7.4. Delaying Pubertal Development. Central precocious
puberty develops in children with CAH when adequate
suppression of ACTH (and androgens) follows a period of
chronic adrenal androgen overexposure due to inadequate
c o r t i s o lr e p l a c e m e n t .F o rb o t hs e x e s ,a d v a n c e dB Ai sag o o d
predictor of which children are most likely to develop central
precocious puberty [41]. The diagnosis of central precocious
puberty is conﬁrmed when GnRH stimulation testing shows
a robust LH response that exceeds that of FSH and when
accompanied by additional clinical and laboratory features
of puberty. Girls may receive a baseline pelvic ultrasound
to obtain uterine measurements and assess the presence or
absence of an endometrial stripe prior to the initiation of
treatment [42, 43]. GnRH agonists (GnRHa) are eﬀective at
preventing further progression of the clinical signs of central
precocious puberty when coupled with appropriate glu-
cocorticoid and mineralocorticoid replacement [41]. Such
treatment can be administered either as daily sc, monthly
depot injections, or implants [44]. During GnRHa therapy
monitoring of Tanner stages, height, and growth velocity
should occur every 3-4 months. Therapy may be continued
until the child reaches the chronological age when puberty
is expected and either: (1) the BA and current height predict
that a normal adult height can be reached, or (2) the growth
velocity is so slow and the BA so far advanced that there is
little to gain with continued treatment.
7.5. Adjunctive Therapies. The adult height of those with
classical forms of CAH can be signiﬁcantly compromised
[19]. Adjunctive therapies have been proposed to improve
ﬁnal height including GnRHa to delay the onset of puberty
beyond the normal age in order to extend the period of
growth.Thoughmodesteﬀectshavebeenreported[45],such
treatment is considered experimental at this time [46].
Other adjunctive therapies considered for use in people
aﬀected by CAH include medications for limiting the eﬀects
of androgens and estrogens on virilization and bone mat-
uration, respectively. For example, treating with ﬂutamide
(an antiandrogen) and testolactone (an aromatase inhibitor)
allows for a more physiologic replacement dose of cortisol
to be administered to patients without an acceleration
of growth or untoward BA advancement [47]. Although
encouraging, data on such treatment approaches are limited
and thus these therapies are not part of our routine
management of patients—most of whom reach an adult
heightwithinthenormalrangedespitehavingreceivedsolely
conventional hormone replacement [24].
7.6. Bone Health. Chronic use of glucocorticoids both
increases bone resorption and decreases bone formation
[48, 49]. A review of data reveals contradictory results
of the potentially adverse eﬀects of chronic glucocorticoid
replacement on bone health in both children and adults
with CAH. Several studies in adults reveal decreased bone
mineraldensity(BMD)withtreatment[50–53],whileothers
report no eﬀect [54, 55]. Similarly, in young adults and
children with CAH some studies fail to detect an eﬀect of
glucocorticoid replacement [56, 57] while others observe
decreased BMD [58]. Overall, these data are limited by
several factors including failure to match for race and age
between those aﬀected by CAH and controls, as well as the
diﬃculty of interpreting bone densitometry data in children.
Observations of lower BMD, as well as increased occur-
rence of fractures, exist for women with CAH [59]. For
younger patients our goal is to avoid over-suppression with
glucocorticoids and emphasizing the importance of vitamin
D and calcium intake. For older patients, a baseline dual
energy X-ray absorptiometry (DXA) measure is ordered
when epiphyseal fusion is complete.
8.Limiting AdverseResponses to GenitalExam-
inationsandMedicalPhotography
The 2002 consensus statement recommends that “The prior
practice of frequent genital examinations in females should
be abandoned [4].” The consensus advises that genital exams
be performed only in light of evidence of poor medical
compliance. This recommendation is in response to adverse
patient reactions to medical photography and genital exams
[60]. Residents and rotating medical students may be present
during patient genital exams, with the permission of the
child’s parents, until the patient (female or male) is 2
years of age. Subsequently, only the endocrine and urology
attending physicians and fellows perform genital exams on
aﬀectedchildren,andeveryattemptismadetoperformthese
examinations together to avoid frequent exposure. Medical
photography, following informed consent of parents, may be
doneupto1yearofageintheclinic.Afterthatpoint,medical
photography is only obtained when the patient is sedated
following appropriate consent. In our clinic this standard is
applied to both sexes.
9.SurgicalManagement
Females aﬀected by CAH due to 21-OH deﬁciency com-
prise the largest diagnostic group of individuals born with
ambiguous genitalia. According to the 2002 consensus state-
mentthegoalsoffeminizinggenitoplastyinaﬀectedgirlsand
women are: (1) to create a female genital appearance, (2) to
create unobstructed urinary emptying free of incontinence
or infections, and (3) to allow for good adult sexual
and reproductive function [4] .T h e r ea r es e v e r a lt y p e so f
surgical procedures for genital feminization; however, there
are limited long-term outcome data regarding success rates
for achieving desired results. Additionally, disagreement
exists about the optimal timing for these procedures to be
performed throughout development.
For parents and patients who choose feminizing geni-
toplasty, procedures can include clitoroplasty, labial recon-
struction and vaginoplasty. Regarding clitoroplasty, totalInternational Journal of Pediatric Endocrinology 7
excisions were performed prior to the 1980s (see Table 2).
More recently, the medical community has recognized that
clitoroplasty that preserves the glans and neurovascular
bundle of the clitoris will inevitably demonstrate improve-
ment in long-term sexual function [61–66]. Concerning
vaginoplasty, the type of procedure employed depends on
the point of entry of the vagina into the urogenital sinus.
In most of the studies reviewed (see Table 2)aF o r t u n o ﬀ
posterior ﬂap vaginoplasty was performed if the point of
entry was low (Prader I-III) and a pull-through procedure
was performed if the point of entry was high (Prader IV-
V). A recent modiﬁcation of pull-through vaginoplasty is
partial urogenital sinus mobilization (PUM). Good cosmetic
outcome is associated with this procedure; however, due to
the fact that this is a recent modiﬁcation functional outcome
data are lacking at this time [67].
A review of feminizing genitoplasty outcome data pub-
lished since 2000 reveals clinically relevant observations.
First, clitoroplasty can, but does not always, lead to normal
clitoral sensation and orgasmic potential even when the
dorsal nerves are preserved and surgery is limited to a single
procedure [63, 64, 66, 70]. While procedures that preserve
dorsal nerve function appear to oﬀer a beneﬁt over total
excision [70], only a third of women who have received
this type of procedure report sensitivity to temperature and
vibration that is similar to unaﬀected women [66]. To opti-
mize the likelihood of a satisfactory outcome of clitoroplasty,
it is recommended that only experienced surgeons perform
this surgery [4, 69]. Finally, parents can be reassured that
an aﬀected girl’s clitoris will appear smaller as she grows
if adrenal androgen production is appropriately suppressed
withglucocorticoidreplacement.Thus,aclitoristhatappears
large in infancy might look normal in an adolescent even
when clitoroplasty has not been performed.
A second conclusion from our review of surgical
outcome data is that the size of the introitus, but not the
length of the vagina, is often too small in women who have
received a vaginoplasty [64, 68]. Those who have received a
vaginoplasty are more likely to report infrequent intercourse
and diﬃculties with vaginal penetration compared to those
who have not undergone this surgery [63, 66]. Additionally,
girls born with more severe genital masculinization are more
likely to require multiple procedures to create a functioning
vagina and less likely to engage in vaginal penetration
than those born with a lesser degree of masculinization
[61, 63, 65].
These outcomes reveal some of the diﬃculties associated
with feminizing genitoplasty. Despite these problems, it is
unclear if such procedures should be abandoned in total.
This is because comparisons between girls and women with
CAH who received genitoplasty versus those who did not
are confounded by the fact that those who do not receive
surgery are typically less masculinized at birth. As poor
cosmetic and sexual function outcomes are associated with
greater genital masculinization at birth and diﬀerent types of
procedures employed [62–64], simple comparisons between
these groups are problematic. Additionally, dissatisfaction
with cosmetic appearance and function of the genitalia
are reported even among women with CAH who did not
receive genitoplasty [64]. Finally, early genitoplasty can
result in a satisfactory cosmetic outcome when performed
by experienced surgeons who function as members of an
interdisciplinary team such as that described here [69]. It is
currently not possible to know how representative women
arethose who oppose early surgery,andsome patients report
that infancy is the optimal time for such treatment [62, 64].
Surgeons have compromised by stating that vaginoplasty
can be delayed if it is the only procedure required for
feminization of the genitalia; however, when other genital
surgery is needed or when symptoms such as urinary tract
infections are present, early vaginoplasty is indicated [71].
A female infant referred to The Children’s Hospital of
Oklahoma will receive a cystoscopy and vaginoscopy at
approximately 3–6 months of age if these procedures have
not already been performed. A pediatric urologist and child
psychiatrist discuss the pros and cons of genitoplasty, based
on current literature, with families and patients considering
such procedures. In accordance with the 2002 consensus
statement,itisrecommendedthatgenitoplastybeperformed
at around 12 months of age [4]. When the point of entry
of the vagina into the urogenital sinus is low, a single-
stageclitoroplasty/vaginoplastymaybeperformed.Thegoals
of this surgery are to reduce the size of the phallus while
preservingtheglansanddorsalnerveﬁbersaswellastobring
the vaginal oriﬁce to the perineal surface while separating it
from the urethral opening.
10. Effectivenessof anEvidence-Based,
MultidisciplinaryTeam Approach
toward CAH
A review of the clinical management of medical conditions
such as CAH from 23 European countries reveals that most
centers interviewed provide subspecialty support to patients
and families including mental health services [72]. Thus,
professionals are implementing the consensus statement
recommendations in their clinical practice. In an attempt
to quantify the eﬀectiveness of our team’s protocol, we
analyzed data from 14 families who attended our clinic
both prior to, and following, the implementation of our
evidence-based, multidisciplinary approach toward treating
21-OH deﬁciency. Six outcomes were assessed—3 related to
medicalmanagementand3relatedtomentalhealthandpeer
support.
First, we investigated if the recommended laboratory
tests were obtained for patients more consistently following
the implementation of our protocol. Signiﬁcantly more
patients obtained laboratory tests recommended by the 2002
consensus statement after our team and protocol were in
place (X2(1) = 5.12, P<. 05). Although not statistically
signiﬁcant, there was evidence for improvement in obtaining
BA (X2(1) = 3.0, P = .08) data according to the 2002
consensus recommendation [4]. No change was observed for
obtaining unnecessary laboratory tests (P>. 05).
Concerningmentalhealthandpeersupport,signiﬁcantly
more patients and parents met with a mental health provider8 International Journal of Pediatric Endocrinology
Table 2: Review of cosmetic and functional outcome studies of feminizing genitoplasty in girls and women with congenital adrenal
hyperplasia due to 2-hydroxylase deﬁciency conducted from 2000–present.
Dependent
Measure
Sample size; age
range (y)a t
participation
Earliest surgery dates; age
range (y) of earliest surgery Summary Reference
Cosmetic
appearance
27; 14.0–33.0
1970s–1980s; 2.4–9.9
(i) combination of clitoral
excision and reduction as
well as fortunoﬀ ﬂap or
pull through vaginoplasty
(i) participants (n = 6) who
experienced vaginal stenosis
secondary to their vaginoplasty
were less satisﬁed than the
authors with the appearance of
their genitalia
[61]
21; 7.0–19.0
1970s–1980s; 0.8–10.4
(i) majority received
clitoral reduction and
fortunoﬀ vaginoplasty
(i) 24% had a “good” outcome as
determined by the authors
(ii) most required more than a
single-stage genitoplasty
[68]
23; 21.0–71.0
1950s–1990s; 0.3–20.0
(i) majority received
clitoral excision and
fortunoﬀ vaginoplasty
(i) author ratings of the
appearance of the genitals were
better than self-ratings
[62]
15; 12.0–25.0
1980s–1990s; <2.0–>2.0
(i) combination of clitoral
excision, reduction and
recession as well as V-Y
vaginoplasty and vaginal
pull-through
(i) Equally good cosmetic
outcome for participants who
had surgery prior to 2 years of
age versus after 2
(ii) Better cosmetic outcome for
planned one-stage surgery than
planned multistage
(iii) Better cosmetic outcome
when the procedures were
performed at an institution and
by a surgeon with expertise in
DSD
[69]
24; 2.0–17.0
1990s–2000s; 0.1–16.0
(i) all received partial
urogenital sinus
mobilization and clitoral
resection with preservation
of neuron-vascular bundle
and glanular reloaction,
half received glanular
reduction
(i) 87.5% had a “good” outcome
as determined by the authors
[67]
35; 18.0–43.0
1950s–1990s; 0.5–18.0
(i) combination of clitoral
excision and resection as
well as fortunoﬀ or
pull-through vaginoplasty
( i )m a j o r i t yh a da“ g o o d ”
outcome as determined by the
authors and self-report
(ii) mean genital surgeries <2
[63]
49; 18.0–63.0
1950s–2000s; 0.5–20.0
(i) combination of clitoral
excision, recession and
resection as well as simple
cleavage and fortunoﬀ
vaginoplasty
(i) majority of women receiving
clitoral surgery rated their
clitoral size as “normal” versus
majority of women not receiving
s u r g e r yr a t e st h e i rc l i t o r i sa s“ t o o
big”
(ii) unsatisfactory appearance
attributed to size/location of
clitoris and scar tissue in women
who had received genitoplasty
(iii) mean genital surgeries >2
[64]International Journal of Pediatric Endocrinology 9
Table 2: Continued.
Dependent
Measure
Sample size; age
range (y)a t
participation
Earliest surgery dates; age
range (y) of earliest surgery Summary Reference
Sexual function
27; 14.0–33.0
1970s–1980s; 2.4–9.9
(i) combination of clitoral
excision and reduction as
well as fortunoﬀ ﬂap or
pull through vaginoplasty
(i) women born
with greater masculinization
of their genitalia (Prader
III or greater) are more likely
to develop intravaginal stenosis
if they received a single-stage
vaginoplasty prior to puberty
(ii) participants (n = 6) who
experienced vaginal stenosis sec-
ondary to their vaginoplasty were
less satisﬁed with their degree of
vaginal opening than examiners
[61]
23; 21.0–71.0
1950s–1990s; 0.3–20.0
(i) majority received
clitoral excision and
fortunoﬀ vaginoplasty
(i) women born with greater
genital masculinization
(salt-losing or SL) reported
poorer sexual function than
those with less masculinization
(simple-virilizing or SV)
following genitoplasty
(ii) SL women had a shorter
vagina than SV women following
genitoplasty
[62]
41; 16.0–46.0
1960s–2000s;
infancy–puberty
(i) combination of clitoral
excision and resection as
well as fortunoﬀ or
pull-through vaginoplasty
(i) 1 in 6 women born with less
masculinized genitalia who did
not receive genitoplasty were
unable to have sexual intercourse
versus 3 in 29 women born with
more masculinized genitalia who
did receive genitoplasty
(ii) women born with more
masculinized genitalia were more
likely to a 2-stage genitoplasty
[65]
27; 0.1–19.0
1990s–2000s; 0.1–19.0
(i) all received nerve
sparing ventral clitoral
reduction
(i) no large dorsal nerves
visualized in excised erectile
tissuefollowing clitoralreduction
[70]
35; 18.0–43.0
1950s–1990s; 0.5–18.0
(i) combination of clitoral
excision and resection as
well as perineal or
pull-through vaginoplasty
(i) women born with greater
genital masculinization (Prader
IV-V) prior to genitoplasty have
fewer sex partners and fewer
episodes of vaginal penetration
than less masculinized
women (Prader I–III) or controls
(ii) Prader IV-V women experi-
ence more diﬃculties with pain,
lubrication, and orgasm than
Prader I–III women or controls
[63]
63; 2.0–19.3
1985–2000; 0.2–19.6
(i) combination of
fortunoﬀ ﬂap, pull-through
and vaginal replacement
(i) 27% developed vaginal
strictures, 5% developed major
complications including ﬁstulas
and diversion colitis
(ii)the complication rate for
fortunoﬀ ﬂap vaginoplasties
performed in prepubertal
patients was higher than that of
ﬂap procedures performed
postpubertally
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Table 2: Continued.
Dependent
Measure
Sample size; age
range (y)a t
participation
Earliest surgery dates; age
range (y) of earliest surgery Summary Reference
28; 17.0–39.0
1970s–2000s; 4.0–<16.0
(i) combination of clitoral
excision and reduction;
type of vaginoplasty not
reported
(i) CAH women who had
received genitoplasty had less
frequent intercourse and greater
penetration diﬃculty and
anorgasmia than CAH women
who had not received
genitoplasty (n = 4)
(ii) CAH women who had
received genitoplasty were less
sensitive to temperature and
vibration following clitoral
stimulation than controls
(iii) Other measures of sexual
function and avoidance did not
diﬀer between women with CAH
who had received genitoplasty
versus those that did not and
controls
[66]
49; 18.0–63.0
1950s–2000s; 0.5–20.0
(i) combination of clitoral
excision, recession, and
resection as well as simple
cleavage or dorsal ﬂap
vaginoplasty
(i) 20.4% women were
dissatisﬁed with their
genitoplasty
(ii) those who had received
clitoral excision or multiple
clitoral surgeries reported the
least clitoral sensitivity
(iii) 45.6% women reported the
vaginal introitus as “too small”
or “tight” whether they received
vaginoplasty or not
[64]
at least annually (X2(1) = 4.09, P<. 05) after our multi-
disciplinary team and protocol were implemented. Similarly,
more families received structured education about 21-OH
deﬁciency (X2(1) = 15.55, P<. 0005) and participated in
peer support groups (X2(1) = 13.26, P<. 0005) following
our attempt to translate the 2002 consensus statement
recommendations [4] into standard clinical practice.
The 2002 consensus statement recommends that
“... the management of congenital adrenal hyperplasia
(CAH) remains diﬃcult, and clinical practice varies
substantially throughout the world [4] . ”W eh a v ea t t e m p t e d
to interpret and translate the 2002 consensus statement
recommendations into an evidence-based protocol when
possible. Additionally, we have shown that this protocol is
eﬀective at improving medical and mental health services
to patients and their families. Future works is needed to
determine the sustainability of such clinics, as well as their
ability to improve long-term health outcomes and quality of
life for patients.
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